MA26859A1 - Forme posologique de medicament commandée par un hydrogel. - Google Patents

Forme posologique de medicament commandée par un hydrogel.

Info

Publication number
MA26859A1
MA26859A1 MA26695A MA26695A MA26859A1 MA 26859 A1 MA26859 A1 MA 26859A1 MA 26695 A MA26695 A MA 26695A MA 26695 A MA26695 A MA 26695A MA 26859 A1 MA26859 A1 MA 26859A1
Authority
MA
Morocco
Prior art keywords
drug
dosage form
water
hydrogel
nucleus
Prior art date
Application number
MA26695A
Other languages
English (en)
Inventor
Elizabeth Appel Leah
Arthur Beyerinck Ronald
Brian Chidlaw Mark
John Curatolo William
Thomas Friesen Dwayne
Lincoln Smith Kelly
Govind Thombre Avinash
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA26859A1 publication Critical patent/MA26859A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DEPOSANT Sociétés dites : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 23/12/1999 60/171,968 Voir en annexe le titre de l'invention et le texte de l'abrégé "Forme posologique de médicament commandée par un hydrogel" Une forme posologique à libération contrôlée comprend un noyau enrobé, le noyau comprenant une composition contenant un médicament et une composition pouvant gonfler dans l'eau, chacune occupant des régions distinctes dans le noyau. La composition contenant un médicament comprend un médicament à faible solubilité et un agent d'entraînement de médicament. L'enrobage autour du noyau est perméable à l'eau et insoluble dans l'eau et comporte au moins un orifice de libération. Diverses formulations ayant des profils spécifiques de libération de médicament sont décrites.
MA26695A 1999-12-23 2002-06-18 Forme posologique de medicament commandée par un hydrogel. MA26859A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17196899P 1999-12-23 1999-12-23

Publications (1)

Publication Number Publication Date
MA26859A1 true MA26859A1 (fr) 2004-12-20

Family

ID=22625827

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26695A MA26859A1 (fr) 1999-12-23 2002-06-18 Forme posologique de medicament commandée par un hydrogel.

Country Status (42)

Country Link
US (3) US20020015731A1 (fr)
EP (2) EP1242055B1 (fr)
JP (1) JP4100910B2 (fr)
KR (1) KR100523127B1 (fr)
CN (1) CN1402632A (fr)
AP (1) AP2002002553A0 (fr)
AR (1) AR027091A1 (fr)
AT (1) ATE392890T1 (fr)
AU (1) AU783685B2 (fr)
BG (1) BG106865A (fr)
BR (1) BR0016708A (fr)
CA (1) CA2395333C (fr)
CR (1) CR6656A (fr)
CZ (1) CZ20022046A3 (fr)
DE (1) DE60038698T2 (fr)
DK (1) DK1242055T3 (fr)
DZ (1) DZ3228A1 (fr)
EA (1) EA004370B1 (fr)
EE (1) EE200200361A (fr)
ES (1) ES2302705T3 (fr)
GE (1) GEP20043334B (fr)
GT (1) GT200000222A (fr)
HU (1) HUP0301242A3 (fr)
IL (1) IL149224A0 (fr)
IS (1) IS6340A (fr)
MA (1) MA26859A1 (fr)
MX (1) MXPA02006328A (fr)
NO (1) NO20022970L (fr)
NZ (1) NZ518281A (fr)
OA (1) OA12128A (fr)
PA (1) PA8509001A1 (fr)
PE (1) PE20010985A1 (fr)
PL (1) PL357535A1 (fr)
PT (1) PT1242055E (fr)
SI (1) SI1242055T1 (fr)
SK (1) SK8572002A3 (fr)
SV (1) SV2002000250A (fr)
TN (1) TNSN00253A1 (fr)
TR (1) TR200201646T2 (fr)
WO (1) WO2001047500A1 (fr)
YU (1) YU35302A (fr)
ZA (1) ZA200204960B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY26615A1 (es) 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20100196466A1 (en) * 2000-06-06 2010-08-05 Capricorn Pharma Inc. Drug delivery system
US20070059367A1 (en) * 2000-06-06 2007-03-15 Cherukuri S R Drug Delivery System and Associated Methods
US7678387B2 (en) * 2000-06-06 2010-03-16 Capricorn Pharma, Inc. Drug delivery systems
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2450748A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
CN1268338C (zh) 2001-07-06 2006-08-09 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的口服给药
BR0307332A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
ES2305434T3 (es) 2002-02-01 2008-11-01 Pfizer Products Inc. Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
AU2003269744A1 (en) * 2002-05-15 2003-12-02 Sun Pharmaceutical Industries Limited Oral osmotic controlled drug delivery system
US20040076668A1 (en) * 2002-07-03 2004-04-22 Pfizer Inc. Controlled-release pharmaceutical formulations
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
EA011579B1 (ru) * 2003-02-07 2009-04-28 Актавис Груп Хф Композиция с пролонгированным высвобождением венлафаксина
WO2004098572A1 (fr) * 2003-05-06 2004-11-18 Ranbaxy Laboratories Limited Liberation biphasique de glipizide contenu dans une forme pharmaceutique osmotique monocompartiment
WO2005011635A2 (fr) 2003-08-04 2005-02-10 Pfizer Products Inc. Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
US8715724B2 (en) * 2004-10-29 2014-05-06 Mayne Pharma International Pty Ltd Tabletting process
WO2006072878A1 (fr) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Formes posologiques orales de sertraline possedant une taille de particule controlee, et leurs procedes de preparation
GB0504547D0 (en) * 2005-03-04 2005-04-13 Delsol Products Ltd Personal lubricant
EP1858493A4 (fr) * 2005-03-14 2010-12-01 Sun Pharmaceutical Ind Ltd Systeme d'administration de medicament par voie orale
US7541347B2 (en) 2007-04-02 2009-06-02 Medicis Pharmaceutical Coropration Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US20080242642A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8722650B1 (en) 2005-06-24 2014-05-13 Medicis Pharmaceutical Corporation Extended-release minocycline dosage forms
US7919483B2 (en) * 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7544373B2 (en) * 2007-04-02 2009-06-09 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
WO2007057762A2 (fr) * 2005-11-16 2007-05-24 Pfizer Limited Forme posologique a liberation controlee
US20080241197A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline dosage forms for the treatment of acne
CN101439026B (zh) * 2007-11-23 2011-04-06 北京红林制药有限公司 含有多沙唑嗪或其盐的控释制剂及其制备方法
BRPI0908114A2 (pt) * 2008-02-15 2015-10-06 Sun Pharma Advanced Res Co Ltd tabuleta oral de liberação controlada
WO2010017310A1 (fr) 2008-08-06 2010-02-11 Medicis Pharmaceutical Corporation Procédé pour le traitement de l'acné, et certaines formes posologiques de celui-ci
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
KR101284368B1 (ko) 2010-07-09 2013-07-15 서울대학교산학협력단 나노섬유시트 기재의 경구용 약물의 제어 전달을 위한 시스템
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) * 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9561241B1 (en) 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
US9918937B2 (en) * 2013-01-30 2018-03-20 Daewoong Co., Ltd. Pharmaceutical composition for protecting wounds, providing hemostasis, or preventing adhesion in the gastrointestinal tract
MX2015012416A (es) * 2013-03-14 2016-04-07 Amgen Inc Compuestos heterociclicos y sus usos.
DK2970123T3 (da) 2013-03-14 2019-10-21 Amgen Inc Salt af omecamtiv mecarbil og fremgangsmåde til fremstilling heraf
US20170182070A1 (en) 2014-10-08 2017-06-29 Mayne Pharma International Pty Ltd. Controlled Release Doxycycline
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
EP3340982B1 (fr) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Composés pour le traitement de troubles immunitaires et inflammatoires
RU2018145364A (ru) 2016-06-27 2020-07-28 Ачиллион Фармасьютикалс, Инк. Хиназолиновые и индольные соединения для лечения медицинских нарушений
US20230022157A1 (en) 2018-08-20 2023-01-26 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
EP3866773A4 (fr) 2018-10-16 2022-10-26 Georgia State University Research Foundation, Inc. Promédicaments de monoxyde de carbone pour le traitement de troubles médicaux
CN115768410A (zh) * 2020-07-10 2023-03-07 阿代尔制药股份有限公司 可溶胀的口服药物组合物
IL301389A (en) 2020-09-18 2023-05-01 Bristol Myers Squibb Co Dosage forms for TYK2 inhibitors that include swellable cores
TW202325285A (zh) * 2021-10-14 2023-07-01 靜岡縣公立大學法人 粉末製劑
WO2023154171A1 (fr) * 2022-02-14 2023-08-17 Purdue Research Foundation Sels polymères destinés à améliorer l'administration de médicament à partir de dispersions solides amorphes

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IT1165797B (it) * 1982-10-18 1987-04-29 Consiglio Nazionale Ricerche Procedimento di preparazione di alchilangelicine esenti da psoraleni ed alchilangolicine ottenute col procedimento
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
GB8322007D0 (en) * 1983-08-16 1983-09-21 Wellcome Found Pharmaceutical delivery system
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
DE3868077D1 (de) * 1987-01-14 1992-03-12 Ciba Geigy Ag Therapeutisches system fuer schwerloesliche wirkstoffe.
US4851232A (en) 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4795641A (en) * 1987-08-20 1989-01-03 Eastman Kodak Company Polymer blends having reverse phase morphology for controlled delivery of bioactive agents
US5612059A (en) 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5151450A (en) * 1990-02-22 1992-09-29 Tokyo Tanabe Company, Limited Antiulcer substance
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5431921A (en) * 1990-09-28 1995-07-11 Pfizer Inc Dispensing device containing a hydrophobic medium
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
ZA927779B (en) * 1991-10-10 1993-07-05 Alza Corp Osmotic drug delivery devices with hydrophobic wall materials.
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
CZ291495B6 (cs) * 1992-09-18 2003-03-12 Yamanouchi Pharmaceutical Co., Ltd. Hydrogelotvorný farmaceutický přípravek s prodlouženým uvolňováním
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
ES2149250T3 (es) * 1993-04-23 2000-11-01 Novartis Ag Dispositivo para la administracion de medicamentos con liberacion controlada.
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
HU213407B (en) * 1993-12-09 1997-06-30 Egyt Gyogyszervegyeszeti Gyar Process for producing tablet with diffusive-osmotic release
GB9326267D0 (en) * 1993-12-23 1994-02-23 Scherer Corp R P Expulsion of material
US5458887A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5458888A (en) * 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
PL179910B1 (pl) * 1994-05-06 2000-11-30 Pfizer Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5582591A (en) * 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
US5607696A (en) * 1995-02-10 1997-03-04 Alza Corporation Osmotic membrane and delivery device
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5654005A (en) * 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
FR2744733B1 (fr) * 1996-02-08 1998-04-24 Ascometal Sa Acier pour la fabrication de piece forgee et procede de fabrication d'une piece forgee
IT1290764B1 (it) * 1996-05-03 1998-12-10 Vevy Europ S P A Pentapeptide per la preparazione di composizioni dermo- farmaceutiche e cosmetiche per il trattamento di lesioni od affezioni cutanee
US5837379A (en) * 1997-01-31 1998-11-17 Andrx Pharmaceuticals, Inc. Once daily pharmaceutical tablet having a unitary core
US6271278B1 (en) * 1997-05-13 2001-08-07 Purdue Research Foundation Hydrogel composites and superporous hydrogel composites having fast swelling, high mechanical strength, and superabsorbent properties
CA2261787C (fr) * 1997-05-30 2006-11-14 Laboratorios Phoenix U.S.A., Inc. Dispositif a osmose multicouches
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
DE60042352D1 (de) * 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6245200B1 (en) 1999-12-10 2001-06-12 Sandia Corporation Photo-oxidation method using MoS2 nanocluster materials
JP2003518487A (ja) * 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク ヒドロゲル駆動型積層薬物製剤
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form

Also Published As

Publication number Publication date
YU35302A (sh) 2005-03-15
AU783685B2 (en) 2005-11-24
US20020015731A1 (en) 2002-02-07
PT1242055E (pt) 2008-07-02
AP2002002553A0 (en) 2002-06-30
SI1242055T1 (sl) 2008-08-31
IL149224A0 (en) 2002-11-10
US20070087057A1 (en) 2007-04-19
KR20020070330A (ko) 2002-09-05
CA2395333A1 (fr) 2001-07-05
NO20022970D0 (no) 2002-06-20
DZ3228A1 (fr) 2001-07-05
JP4100910B2 (ja) 2008-06-11
ATE392890T1 (de) 2008-05-15
EP1242055B1 (fr) 2008-04-23
CN1402632A (zh) 2003-03-12
BR0016708A (pt) 2002-10-08
HUP0301242A3 (en) 2006-07-28
NZ518281A (en) 2005-01-28
DK1242055T3 (da) 2008-07-21
DE60038698T2 (de) 2009-05-07
PE20010985A1 (es) 2001-09-28
ES2302705T3 (es) 2008-08-01
EA200200595A1 (ru) 2002-12-26
KR100523127B1 (ko) 2005-10-20
IS6340A (is) 2002-04-12
BG106865A (bg) 2003-03-31
SK8572002A3 (en) 2002-12-03
CA2395333C (fr) 2009-01-13
CR6656A (es) 2004-04-29
WO2001047500A1 (fr) 2001-07-05
HUP0301242A2 (hu) 2004-05-28
EA004370B1 (ru) 2004-04-29
US20110182947A1 (en) 2011-07-28
TR200201646T2 (tr) 2002-11-21
TNSN00253A1 (fr) 2002-05-30
NO20022970L (no) 2002-06-20
CZ20022046A3 (cs) 2002-11-13
JP2003518489A (ja) 2003-06-10
PL357535A1 (en) 2004-07-26
AR027091A1 (es) 2003-03-12
GT200000222A (es) 2002-06-14
US9028870B2 (en) 2015-05-12
DE60038698D1 (de) 2008-06-05
OA12128A (en) 2006-05-05
EP1967185A1 (fr) 2008-09-10
AU2018901A (en) 2001-07-09
MXPA02006328A (es) 2002-12-13
ZA200204960B (en) 2003-10-02
GEP20043334B (en) 2004-03-10
SV2002000250A (es) 2002-02-05
EP1242055A1 (fr) 2002-09-25
EE200200361A (et) 2003-10-15
PA8509001A1 (es) 2002-02-21

Similar Documents

Publication Publication Date Title
MA26859A1 (fr) Forme posologique de medicament commandée par un hydrogel.
TNSN01123A1 (fr) Formes posologiques nouvelles a liberation controlee
BR0014159A (pt) Combinação farmacêutica de etinilestradiol e drospirenona para uso como um anticoncepcional
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
KR910009243A (ko) 치근막 질환 치료용 서방성 조성물
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
FR2752732B1 (fr) Forme galenique a liberation prolongee de milnacipran
NO20043871L (no) Legemiddelformuleringer med kontrollert frigjoring som inneholder et baererpeptid
EP0966966A3 (fr) Forme posologique de néfadozone
KR950702409A (ko) 방출 조절 모르핀 제제(controlled release morphine preparation)
CA2371940A1 (fr) Amidon pregelatinise dans une formulation a liberation regulee
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
EP0382066A3 (fr) Utilisation de l'acide dihydroliponique comme agent analgésique, antiphlogistique et/ou cytoprotecteur
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
HUP0004173A2 (hu) Immunszuppresszív szereket tartalmazó, helyileg alkalmazható szemgyógyászati készítmények
DE69922017D1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
DK1187611T3 (da) Oftalmiske histaminholdige sammensætninger og anvendelse deraf
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
GEP20043377B (en) Pharmaceutical Complex
DE69634080D1 (de) Mittel zur verhinderung der truebung der vorderen linsenkapsel
WO2001070184A3 (fr) Composition contenant des monoterpenes destinee a une administration orale topique
ATE415964T1 (de) Abführzusammensetzung,welche l-arginine enthält
UY26503A1 (es) " forma de dosificación de fármacos accionada por un hidrogel"
JO2213B1 (en) A pharmaceutical composition for use as a contraceptive method